Page last updated: 2024-10-25

chlorpromazine and Acute Confusional Senile Dementia

chlorpromazine has been researched along with Acute Confusional Senile Dementia in 36 studies

Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.

Research Excerpts

ExcerptRelevanceReference
" Further drug-like property analysis demonstrated that the optimized compound, 8d (WI-1758), had liver microsomal metabolic stability, was well tolerated (>2000 mg/kg), and had a rational pharmacokinetic profile, as well as an oral bioavailability of 14."1.48Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease. ( Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X, 2018)
" The long-term administration of neuroleptics in severe cases of SDAT caused a significant increase of SLI (p < 0."1.30Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type. ( Cramer, H; Hamann, G; Reuner, C; Schimrigk, K; Strittmatter, M; Strubel, D, 1997)
"Patients with Down syndrome are at high risk for early Alzheimer's disease."1.29Dementia and Down syndrome. ( Shank, JC; Tyler, CV, 1996)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19904 (11.11)18.7374
1990's4 (11.11)18.2507
2000's4 (11.11)29.6817
2010's19 (52.78)24.3611
2020's5 (13.89)2.80

Authors

AuthorsStudies
Marco-Contelles, J1
León, R3
de los Ríos, C1
Samadi, A1
Bartolini, M3
Andrisano, V3
Huertas, O2
Barril, X1
Luque, FJ2
Rodríguez-Franco, MI5
López, B3
López, MG4
García, AG3
Carreiras, Mdo C1
Villarroya, M4
Camps, P1
Formosa, X1
Galdeano, C1
Muñoz-Torrero, D1
Ramírez, L1
Gómez, E1
Isambert, N1
Lavilla, R1
Badia, A1
Clos, MV1
Mancini, F1
Arce, MP4
Dafni, T1
González-Muñoz, GC2
Pérez, C3
Conde, S3
Romero, A1
del Barrio, L1
Martín-de-Saavedra, MD1
Egea, J2
Tang, H3
Zhao, LZ1
Zhao, HT2
Huang, SL2
Zhong, SM2
Qin, JK1
Chen, ZF2
Huang, ZS2
Liang, H2
Wang, ZY1
Sun, Y3
Chen, J1
Chen, X1
Huang, L6
Li, X6
Luo, Z1
Sheng, J1
Lu, C1
Yan, J1
Liu, A1
Luo, HB1
Miao, H1
Meng, F1
Rochais, C1
Lecoutey, C1
Gaven, F1
Giannoni, P1
Hamidouche, K1
Hedou, D1
Dubost, E1
Genest, D1
Yahiaoui, S1
Freret, T1
Bouet, V1
Dauphin, F1
Sopkova de Oliveira Santos, J1
Ballandonne, C1
Corvaisier, S1
Malzert-Fréon, A1
Legay, R1
Boulouard, M1
Claeysen, S1
Dallemagne, P1
Xie, SS3
Wang, X1
Jiang, N2
Yu, W1
Wang, KD1
Lan, JS1
Li, ZR1
Kong, LY1
Wang, Z2
Wang, Y4
Wang, B1
Li, W1
Hroch, L1
Benek, O1
Guest, P1
Aitken, L1
Soukup, O3
Janockova, J1
Musil, K1
Dohnal, V1
Dolezal, R2
Kuca, K2
Smith, TK1
Gunn-Moore, F1
Musilek, K1
Wei, S1
Chen, W1
Qin, J1
Huangli, Y1
Wang, L1
Shen, Y1
Xia, CL1
Wang, N1
Guo, QL1
Liu, ZQ1
Wu, JQ1
Ou, TM1
Tan, JH1
Wang, HG1
Li, D1
Monjas, L1
Gil, C1
De Simone, A1
Baschieri, A1
Apperley, KYP1
Chen, HH1
Guardigni, M1
Montanari, S1
Kobrlova, T1
Valgimigli, L1
Keillor, JW1
Basso, M1
Milelli, A1
Hu, J2
Yang, X1
Feng, X1
Chan, ASC1
Kumar, D1
Gupta, SK1
Ganeshpurkar, A1
Gutti, G1
Krishnamurthy, S1
Modi, G1
Singh, SK1
Hepnarova, V1
Korabecny, J1
Matouskova, L1
Jost, P1
Muckova, L1
Hrabinova, M1
Vykoukalova, N1
Kerhartova, M1
Kucera, T1
Nepovimova, E1
Spilovska, K1
Mezeiova, E1
Pham, NL1
Jun, D1
Staud, F1
Kaping, D1
Pan, T1
An, B1
Li, Z1
Srivastava, P1
Tripathi, PN1
Sharma, P1
Shrivastava, SK1
Liu, J2
Tang, C1
Pang, C1
Li, Q2
Qin, Y1
Nong, X1
Zhang, Z2
Guo, J2
Cheng, M2
Tang, W1
Liang, N1
Jiang, X2
Zhou, J1
Chen, L1
Duan, Y1
Huang, J1
Liu, C2
Chen, Y2
Liu, W2
Sun, H3
Feng, F2
Qu, W1
Xing, C1
Lyu, W1
Wang, S1
Chen, T1
Zhou, W1
Wan, Y1
Wang, R1
Fang, Y1
Jin, Y1
Xi, M1
Feng, C1
Du, K1
Lv, W1
Du, C1
Shen, R1
UMANSKAIA, RM1
PERSSON, I1
Aziz, AA1
Leeming, RJ1
Blair, JA1
Auchus, AP1
Freeman, A1
Green, RC1
Tyler, CV1
Shank, JC1
Strittmatter, M1
Cramer, H1
Reuner, C1
Strubel, D1
Hamann, G1
Schimrigk, K1
Devanand, DP1
Hatch, CD1
Lund, BC1
Perry, PJ1
Asnes, DP1

Other Studies

36 other studies available for chlorpromazine and Acute Confusional Senile Dementia

ArticleYear
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
    Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines

2009
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
    Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases

2009
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
    Journal of medicinal chemistry, 2009, Nov-26, Volume: 52, Issue:22

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly

2009
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel

2011
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood-

2011
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
    Bioorganic & medicinal chemistry letters, 2012, Mar-15, Volume: 22, Issue:6

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra

2012
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
    Bioorganic & medicinal chemistry, 2013, Dec-01, Volume: 21, Issue:23

    Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro

2013
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
    Journal of medicinal chemistry, 2013, Nov-27, Volume: 56, Issue:22

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Azoles; Butyrylcholinestera

2013
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B

2014
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
    Journal of medicinal chemistry, 2015, Apr-09, Volume: 58, Issue:7

    Topics: Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Computer Simulation; Cryst

2015
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
    European journal of medicinal chemistry, 2015, May-05, Volume: 95

    Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel

2015
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
    Journal of medicinal chemistry, 2015, Nov-12, Volume: 58, Issue:21

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Clioquinol; Cognition;

2015
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
    Bioorganic & medicinal chemistry letters, 2016, 08-01, Volume: 26, Issue:15

    Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cel

2016
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
    Bioorganic & medicinal chemistry, 2016, 11-15, Volume: 24, Issue:22

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras

2016
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
    European journal of medicinal chemistry, 2017, Apr-21, Volume: 130

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line;

2017
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
    European journal of medicinal chemistry, 2017, Apr-21, Volume: 130

    Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don

2017
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
    European journal of medicinal chemistry, 2017, Oct-20, Volume: 139

    Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; G

2017
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
    Journal of medicinal chemistry, 2018, 03-08, Volume: 61, Issue:5

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Des

2018
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2018, Apr-25, Volume: 150

    Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Rel

2018
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
    European journal of medicinal chemistry, 2018, Apr-25, Volume: 150

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I

2018
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2019, Feb-01, Volume: 163

    Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester

2019
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
    Bioorganic & medicinal chemistry, 2019, 08-15, Volume: 27, Issue:16

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stres

2019
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
    European journal of medicinal chemistry, 2020, Sep-15, Volume: 202

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose

2020
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
    European journal of medicinal chemistry, 2020, Dec-01, Volume: 207

    Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inh

2020
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
    Bioorganic & medicinal chemistry, 2021, 01-15, Volume: 30

    Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2021
Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzothiazoles; Benzylamines; Biphen

2021
Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.
    Bioorganic & medicinal chemistry letters, 2022, 04-01, Volume: 61

    Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line; Cell Survival; Cholineste

2022
[On the results of aminazin therapy of patients with presenile psychoses].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1960, Volume: 60

    Topics: Alzheimer Disease; Chlorpromazine; Depressive Disorder, Major; Mental Disorders; Psychotic Disorders

1960
[Chlorpromazine in therapy of arteriosclerotic psychosis and senile dementia].
    Nordisk medicin, 1955, Feb-10, Volume: 53, Issue:6

    Topics: Alzheimer Disease; Arteriosclerosis; Chlorpromazine; Dementia; Mental Disorders; Psychotic Disorders

1955
Tetrahydrobiopterin metabolism in senile dementia of Alzheimer type.
    Journal of neurology, neurosurgery, and psychiatry, 1983, Volume: 46, Issue:5

    Topics: Aged; Alzheimer Disease; Biopterins; Chlorpromazine; Female; Humans; Male; Neurotransmitter Agents;

1983
Agitated behavior relieved following treatment of cervical dystonia in dementia.
    Neurology, 1995, Volume: 45, Issue:2

    Topics: Alzheimer Disease; Botulinum Toxins; Chlorpromazine; Dystonia; Female; Humans; Isoxazoles; Middle Ag

1995
Dementia and Down syndrome.
    The Journal of family practice, 1996, Volume: 42, Issue:6

    Topics: Adult; Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Disease Progression; Down Syndrome;

1996
Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type.
    Biological psychiatry, 1997, Jun-01, Volume: 41, Issue:11

    Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Chromatography, High Pressure Liquid;

1997
Antipsychotic treatment in outpatients with dementia.
    International psychogeriatrics, 1996, Volume: 8 Suppl 3

    Topics: Aged; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Dementia; Dose-Respo

1996
Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics.
    Pharmacotherapy, 2001, Volume: 21, Issue:8

    Topics: Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Dibenzothiazepines; Haloperidol; Humans; Hy

2001
Psychopharmacology in the aged. Use of major psychotropic medications in treatment of the elderly: case examples.
    Journal of geriatric psychiatry, 1974, Volume: 7, Issue:2

    Topics: Adjustment Disorders; Aged; Alzheimer Disease; Amitriptyline; Benztropine; Bipolar Disorder; Cataton

1974